Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:QURE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeQUREuniQure$49.04+10.5%$25.97$8.73▼$71.50$2.80B0.982.50 million shs3.44 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceQUREuniQure+10.48%+81.70%+102.73%+199.76%+251.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeQUREuniQure$49.04+10.5%$25.97$8.73▼$71.50$2.80B0.982.50 million shs3.44 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceQUREuniQure+10.48%+81.70%+102.73%+199.76%+251.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceQUREuniQure 2.65Moderate Buy$58.9220.14% UpsideCurrent Analyst Ratings BreakdownLatest QURE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026QUREuniQure Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$35.00 ➝ $65.006/18/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/18/2026QUREuniQure Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $70.006/18/2026QUREuniQure The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$14.00 ➝ $46.006/18/2026QUREuniQure BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$25.00 ➝ $65.006/17/2026QUREuniQure BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingPositive6/17/2026QUREuniQure Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$61.005/6/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $50.005/5/2026QUREuniQure Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$28.004/30/2026QUREuniQure Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $37.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookQUREuniQure$16.10M192.11N/AN/A$3.19 per share15.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateQUREuniQure-$198.97M-$3.48N/AN/AN/A-1,154.42%-145.81%-27.15%8/4/2026 (Estimated)Latest QURE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026QUREuniQure-$0.88-$0.85+$0.03-$0.85$5.21 million$3.56 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthQUREuniQureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioQUREuniQure0.3310.4010.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipQUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipQUREuniQure4.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableQUREuniQure50063.07 million60.13 millionOptionableQURE HeadlinesRecent News About These CompaniesuniQure Announces Pricing of $225 Million Public Offering of Ordinary SharesJune 23 at 9:31 PM | quiverquant.comQuniQure Announces Pricing of Upsized $225 Million Public OfferingJune 23 at 9:13 PM | globenewswire.comuniQure (NASDAQ:QURE) Trading Up 8.3% - Here's WhyJune 23 at 11:59 AM | marketbeat.comuniQure (NASDAQ:QURE) Director Jack Kaye Sells 5,295 Shares of StockJune 23 at 5:32 AM | americanbankingnews.comuniQure (NASDAQ:QURE) CEO Matthew Kapusta Sells 41,671 SharesJune 23 at 4:59 AM | americanbankingnews.comuniQure (NASDAQ:QURE) Director Madhavan Balachandran Sells 11,685 Shares of StockJune 23 at 4:59 AM | americanbankingnews.comInsider Selling: uniQure (NASDAQ:QURE) Director Sells 5,295 SharesJune 23 at 4:21 AM | insidertrades.comuniQure (NASDAQ:QURE) CEO Matthew Kapusta Sells 164,429 SharesJune 23 at 4:09 AM | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), uniQure (QURE)June 23 at 1:59 AM | theglobeandmail.comuniQure Announces $150 Million Proposed Public OfferingJune 22 at 4:01 PM | globenewswire.comUniQure's experimental drug shows early promise in difficult-to-treat epilepsyJune 22 at 3:58 PM | msn.comuniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat EpilepsyJune 22 at 12:11 PM | benzinga.comQURE Announces Initial Data on Gene therapy for Temporal Lobe EpilepsyJune 22 at 11:31 AM | zacks.comuniQure announces preliminary data on first cohort in Phase I/IIa clinical trial of AMT-260June 22 at 7:43 AM | pharmabiz.comPuniQure Announces Promising Early Data for AMT-260June 22 at 7:31 AM | tipranks.comUniQure to seek approval of Huntington’s gene therapy after FDA U-turnJune 20, 2026 | msn.com146,498 Shares in uniQure N.V. $QURE Bought by Flax Pond Capital LLCJune 20, 2026 | marketbeat.comuniQure N.V. $QURE Stock Position Raised by Avoro Capital Advisors LLCJune 20, 2026 | marketbeat.comuniQure (QURE) Stock Could Be 49% Undervalued After FDA AMT 130 UpdateJune 19, 2026 | finance.yahoo.comuniQure (QURE) Is Up 67.9% After FDA Backs AMT-130 Data For Accelerated Approval PathJune 19, 2026 | finance.yahoo.comQURE Soars as FDA Backs AMT-130 Data for Accelerated ApprovalJune 19, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQURE Company DescriptionsuniQure NASDAQ:QURE$49.04 +4.65 (+10.48%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$49.00 -0.04 (-0.08%) As of 07:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
